- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ziosoft offers free 2D/3D software
In the hope of boosting interest in its thin-client visualization system, Ziosoft is providing to the academic and research communities free software for processing 2D and 3D images.
In the hope of boosting interest in its thin-client visualization system, Ziosoft is providing to the academic and research communities free software for processing 2D and 3D images. The Windows-based software, called zioTerm basic 2D/3D, can be used to review DICOM 3.0-compatible imaging data from CT, MR, PET, ultrasound and X-ray on a local computer connected to the Internet. The freeware will provide students and researchers experience using Ziosoft’s core 2D/3D software, according to the company, a long-time provider of advanced visualization in Japan that entered the U.S. market only in the last couple years. The zioTerm software can be downloaded from www.ziosoftinc.com.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
